GS
ZNTL icon

GTS Securities’s Zentalis Pharmaceuticals ZNTL Stock Holding History

GTS Securities’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,500
Closed -$411K – 4472
2023
Q3 		$411K Buy
+20,500
New +$520K ﹤0.01% 2808

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GTS Securities's ZNTL Position: Q4 2023 in Review

GTS Securities sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 9,987 shares — an estimated $200K sold.

GTS Securities first reported a position in ZNTL in Q3 2023 and held it in 1 quarter. The position peaked at $200K in Q3 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • GTS Securities reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • GTS Securities sold 9,987 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $200K.
  • GTS Securities first reported a position in Zentalis Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • GTS Securities's Zentalis Pharmaceuticals position peaked at $200K in Q3 2023.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.